#ovariancancers



Ovarian Cancer and Us - best viewed in FIREFOX

Search: this blog, links from posts and the web.....

Loading...

Friday, November 09, 2012

paywalled: PROGRESS IN OVARIAN CANCER TREATMENT THROUGH GCIG COLLABORATIVE TRIALSCANCER RESEARCH AND CLINICAL ONCOLOGY FOR THE NEXT DECADE



ILPROGRESS IN OVARIAN CANCER TREATMENT THROUGH GCIG COLLABORATIVE TRIALSCANCER RESEARCH AND CLINICAL ONCOLOGY FOR THE NEXT DECADE

Abstract

"Ovarian cancer is a relatively uncommon tumour and progress in treatment has occured through small increments requiring large-scale trials. The Gynecological Cancer InterGroup was formed in 1994 to encourage collaboration and avoid unnecessary repetition of research. Trials conducted by the International Collaborative for Ovarian Neoplasia (ICON) Group and the EORTC, Canadian and Australian groups were the catalysts to bring together a more formal collaboration of established national trials groups.
The aims of the GCIG are to promote international cooperation in clinical research, perform studies in rare tumours, stimulate evidence-based medicine and support educational activities. Over the years, the GCIG has conducted many different trials, including GOG182-ICON5, the largest and fastest recruiting trial in ovarian cancer, held four international consensus conferences on ovarian cancer to review evidence and set standards, and developed strategies for research. A section of the GCIG is directed towards the facilitation of academic research through harmonization of methodologies and developing common approaches to lessen the bureaucracy of clinical trial regulations.
The success of the GCIG results from its relationship between participants, based on mutual respect, equality and recognition of the intellectual contribution from individual group members. Landmark trials that have pushed forward our knowledge will be presented; however, the recognition that ovarian cancer is not a single disease but one with an heterogenous biology underlines the need for a concerted international approach to trials in what are effectively rare tumours. Maintenance of intellectual independence from industry is a major challenge as the costs rise through ever increasing complex trial regulations. However, the current 23 Groups from Europe, North and Central America, Far East and Australia represent a powerful body to influence industry and help direct future research."

0 comments :

Post a Comment

Your opinions and views?